Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis

Journal of Nanobiotechnology

Geoffrey Pietersz¹  Karlheinz Peter²  Haikun Liu³  Xiaowei Wang⁴ 

[1] Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia;Burnet Institute, Melbourne, VIC, Australia;Department of Cardiometabolic Health, University of Melbourne, VIC, Australia;Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia;Department of Cardiometabolic Health, University of Melbourne, VIC, Australia;Department of Medicine, Monash University, Melbourne, VIC, Australia;La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia;Molecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, 3004, Melbourne, VIC, Australia;Molecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, 3004, Melbourne, VIC, Australia;Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia;Department of Cardiometabolic Health, University of Melbourne, VIC, Australia;Department of Medicine, Monash University, Melbourne, VIC, Australia;La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia;

关键词: Antibodies;    Atherosclerosis;    Gene delivery;    Nanoparticles;    Targeted drug delivery;    Thrombosis;   

DOI  :  10.1186/s12951-022-01279-y

来源: Springer

【 摘 要 】

Atherosclerosis and atherothrombosis, the major contributors to cardiovascular diseases (CVDs), represent the leading cause of death worldwide. Current pharmacological therapies have been associated with side effects or are insufficient at halting atherosclerotic progression effectively. Pioneering work harnessing the passive diffusion or endocytosis properties of nanoparticles and advanced biotechnologies in creating recombinant proteins for site-specific delivery have been utilized to overcome these limitations. Since CVDs are complex diseases, the most challenging aspect of developing site-specific therapies is the identification of an individual and unique antigenic epitope that is only expressed in lesions or diseased areas. This review focuses on the pathological mechanism of atherothrombosis and discusses the unique targets that are important during disease progression. We review recent advances in site-specific therapy using novel targeted drug-delivery and nanoparticle-carrier systems. Furthermore, we explore the limitations and future perspectives of site-specific therapy for CVDs.Graphical Abstract

【 授权许可】

CC BY